Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Optic Neuritis × ublituximab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 17 Lymphoma, Non-Hodgkin 7 Lymphoma, Follicular 6 Lymphoma, B-Cell, Marginal Zone 6 Lymphoma, Mantle-Cell 5 Lymphoma, B-Cell 5 Waldenstrom Macroglobulinemia 3 Recurrence 3 Lymphoma 2 Optic Neuritis 1 Neuromyelitis Optica 1 Myelitis, Transverse 1 Lymphoma, Large B-Cell, Diffuse 1 Disease Progression 1

Interventions

eculizumab 3 ublituximab 1 LFB-R603 1 Interferon beta-1a 1 Adrenal Cortex Hormones 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02276963 2019-06-06

Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses

Johns Hopkins University

Phase 1 Completed

6 enrolled 9 charts

Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡